Automated Breast Ultrasound Systems (ABUS) Market Share, Applications, Growth Tr
Posted by priya saraf on September 20th, 2019
Use of conventional handheld ultrasound systems (HHUS) is time consuming and requires technical skills in analyzing the images. The advent of automated breast ultrasound systems (ABUS) has helped alleviate this issue. In 2015, the U.S. Food & Drug Administration (FDA) approved ABUS for supplemental screening of women with dense breasts. Its usage in preoperative evaluation is also increasing in order to identify the presence and amount of cancer tissues, prior to the surgery. Hence, it is vital for ultrasound system manufacturers to closely monitor the various trends in this highly lucrative market and accordingly align their business strategies in order to capitalize on these opportunities.
Request A Sample Copy: http://bit.ly/2kweV9C
High prevalence and incidence rate of breast cancer is a major factor contributing towards growth of automated breast ultrasound systems market. According to the American Cancer Society, 246,660 new cases of breast cancer would be reported in the U.S. in 2016. Moreover, the risk of breast cancer increases with age. Initiatives by the WHO in collaboration with national governments to promote early detection, diagnosis and treatment is further propelling demand for ABUS for breast screening.
However, high costs associated with installation and training of personnel is constraining market growth. Therefore, companies are adopting strategies such as providing FDA approved on-site training, entering into strategic agreements, and introducing innovations in their existing portfolio in order to enhance their market presence.
ABUS are primarily used for screening purpose in adjunct to mammography
ABUS are approved by the U.S. FDA for screening in conjunction with mammography for dense breasts. Radiologists are inclined towards adoption of ABUS as they provide high quality 3D images. Surgeons are adopting this system for pre-operative evaluation of breast to accurately identify the tumor size and location. HHUS are mainly preferred for preoperative evaluation as compared to ABUS, due to high cost associated with ABUS and lack of skilled radiologists to operate the ABUS system during the crucial preoperative period.
High prevalence of breast cancer and awareness campaigns driving demand for ABUS in developed countries
Factors attributable to the growth of ABUS in North America and European markets include increased patient awareness, high uptake of early breast screening, and availability of funds to install relatively expensive ABUS.
According to the World Health Organization (WHO), 232,924 new cases of breast cancer were diagnosed in 2013. Moreover, the American Cancer Society estimates that until 2016 there are over 2.8 million breast cancer survivors in the U.S.
According to the Cancer Research UK, the incidence rate of breast cancer in the U.K is expected to rise by 2% from 2014 to 2035
Public Health England launched a campaign called ‘Be Clear on Cancer’ (2015) to raise breast cancer awareness among women over 70 years. Moreover, research and development in the field is encouraged through the Breast Cancer Now Catalyst Programme (2016).
High prevalence coupled with government awareness drives are driving demand for ABUS in the U.S. and U.K.
Increasing awareness programs related to breast cancer driving demand in Asia-Pacific region
Asia-Pacific possess immense revenue potential for the growth of ABUS market. Demand for ABUS in Asia-Pacific in terms of volume is expected to increase at a CAGR of 24.4% during 2016 – 2024. Lack of awareness had deterred the uptake of early breast screening until various cognizance initiatives were undertaken by ABUS manufacturers and non-profit and regional cancer organizations. Some noteworthy initiatives include The Pink Initiative organization in India, Breast Cancer Initiative East Africa Inc. and Pink Ribbon Breakfast initiative by Cancer Australia. Moreover, denser breast tissues in the Chinese population is driving demand for ABUS in China at a rapid pace.
Automated breast ultrasound systems manufacturers are following inorganic strategies to increase their footprint
Inorganic growth roadmap is the key strategy followed by market leaders. For instance, GE Healthcare acquired U-Systems, Inc. in 2014 to expand their breast care innovations portfolio. Philips partnered with SonoCine, Inc. in 2014 to provide ABUS imaging for its ultrasound systems. Hitachi Aloka Medical America, Inc.
entered into a strategic alliance with iVu Imaging Corporation in 2014, gaining exclusive distribution rights for iVu’s SOFIA (ABUS) system in North America. This agreement helped iVu Imaging Corporation to get access to the expanded channel and also helped both the companies to leverage the technical expertise of the other which further improved the performance of SOFIA.
Click To Read More On: Automated Breast Ultrasound Systems (ABUS) Market
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave,
Seattle, WA 98154
Like it? Share it!
About the Authorpriya saraf
Joined: May 23rd, 2019
Articles Posted: 166
More by this author